Donepezil for dementia in people with Down syndrome

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Mohan, Monica ^a   Carpenter, Peter K ^b   Bennett, Cathy ^c  

^a FRENCHAY HOSPITAL   (United Kingdom)

^b Bath and North Somerset PCT ^*  (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Alzheimer disease *drug therapy; etiology ; Cholinesterase inhibitors *therapeutic use ; Down syndrome *complications ; Humans; Indans *therapeutic use ; Piperidines *therapeutic use ; Randomized controlled trials as topic

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; PLACEBO; RIVASTIGMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ABDOMINAL DISCOMFORT; ADAPTIVE BEHAVIOR; AGITATION; ALZHEIMER DISEASE; ANOREXIA; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITION; COST OF ILLNESS; DEMENTIA; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DIZZINESS; DOWN SYNDROME; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; EMBASE; FATIGUE; FOLLOW UP; GROUPS BY AGE; HUMAN; INSOMNIA; MEDLINE; MENTAL DEFICIENCY; MOOD DISORDER; MORTALITY; MUSCLE CRAMP; NAUSEA; OUTCOME ASSESSMENT; QUESTIONNAIRE; RATING SCALE; REVIEW; SEIZURE; SIDE EFFECT; SKILL; STRESS; TREATMENT DURATION; VOMITING; DRUG ANTAGONISM;

ALZHEIMER DISEASE; DOWN SYNDROME; HUMANS; MEMANTINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 62449325363     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007178.pub2     Document Type: Review

References (68)

1. Prasher VP. Personal communication. Email communications from Prof. V Prasher 24 and 25 April and telephone conversation 7 May 2008 clarifying specifics of the trial conditions April - May 2008.
2. Prasher VP, Adams C, Holder R and The Down Syndrome Research Group. Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study. International Journal of Geriatric Psychiatry 2003; 18:549-551
3. Prasher VP, Huxley A, Haque MS. A 24-week, double-blind, placebocontrolled trial of donepezil in patients with Down syndrome and Alzheimer's disease - pilot study. International Journal of Geriatric Psychiatry 2002;17(3):270-278 (Pubitemid 34232600)
4. Boada-Rovira M, Hernandez-Ruiz I, Badenas-Homiar S, Buendia-Torras M, Tarraga-Mestre L. [Clinical-therapeutic study of dementia in people with Down syndrome and the effectiveness of donepezil in this population]. [Spanish]. Revista De Neurologia 2005;41(3): 129-136
5. Castane M, Boada M, Hernandez I. Study of the visual quality in adults with Down's syndrome. SD Revista Medica Internacional Sobre El Sindrome De Down 2004;8(1):2-7. (Pubitemid 39642732)
6. Cipriani G, Bianchetti A, Trabucchi M. Donepezil use in the treatment of dementia associated with Down's syndrome. Arch Neurol 2003;60(2):292.
7. Heller JH, Spiridigliozzi GA, Sullivan JA, Doraiswamy PM, Krishnan RR, Kishnani PS. Donepezil for the treatment of language deficits in adults with down syndrome: A preliminary 24-week open trial. American Journal of Medical Genetics 2003;116(2):111-116
8. Heller JH, Spiridigliozzi GA, Doraiswamy PM, Sullivan JA, Crissman BG, Kishnani PS. Donepezil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial. American Journal of Medical Genetics. Part A 2004;130(3):325-326
9. Hemingway-Eltomey JM, Lerner AJ. Adverse effects of donepezil in treating Alzheimer's disease associated with Down's syndrome. American Journal of Psychiatry 1999;156(9):1470.
10. Johnson N, Fahey C, Chicoine B, Chong G, Gitelman D. Effects of donepezil on cognitive functioning in Down syndrome. American Journal on Mental Retardation 2003;108(6):367-372 (Pubitemid 37346055)
11. Kishnani PS, Sullivan JA, Walter B, Spiridigliozzi GA, Doraiswamy PM, Krishnan KRR. Cholinergic therapy for Down's syndrome. Lancet 1999;353(9158):1064-1065
12. Kishnani PS, Spiridigliozzi GA, Heller JH, Sullivan JA, Doraiswamy PM, Krishnan KR. Donepezil for Down's syndrome.[comment]. American Journal of Psychiatry 2001;158(1):143.
13. Kondoh T, Amamoto N, Doi T, Hamada H, Ogawa Y, Nakashima M, et al. Dramatic improvement in Down syndrome-associated cognitive impairment with donepezil.[see comment]. Annals of Pharmacotherapy 2005;39(3):563-566 (Pubitemid 40270928)
14. Kondoh T, Nakashima M, Sasaki H, Moriuchi H. Pharmacokinetics of donepezil in Down syndrome. Annals of Pharmacotherapy 2005; 39(3):572-573
15. Lott IT, Osann K Doran E Nelson L. Downs Syndrome and Alzheimer Disease. Arch Nerol July 2002;59:1133-1136.
16. Albert M, Cohen C. The test for severe impairment: an instrument for the assessment of patients with severe cognitive dysfunction. Journal of the American Geriatric Society 1992;40:449-453
17. Alzheimer's Australia (in collaboration with the Down syndrome Association of Victoria). Down syndrome and Alzeimer's disease (available online at: http://www.alzheimers.org.au/upload/HS1.18.pdf; accessed November 2008). Vol. Sheet 1.18, Hawker, ACT: Alzheimer's Australia, 2005 (July).
18. American Association on Intellectual and Developmental Disabilities. Fact Sheet: AGING Older Adults and Their Aging Caregivers (available online: http://www.aaidd.org/Policies/faq-aging.shtml; accessed November 2008). Washington, DC: AAIDD, 2008 (6 August, date of last update).
19. Anon. Cholinesterase inhibitors and cardiac arrhythmias. Australian Adverse Drug Reactions Bulletin October 2004; Vol.23, issue 5: 19-20.
20. Aylward EH, Burt DB, Thorpe LU, et al. Diagnosis of dementia in individuals with intellectual disability. Journal of Intellectual Disability Research 1997;41:152-164 (Pubitemid 27424986)
21. Ball SL, Holland AJ, Huppert FA, Treppner P, Watson P, Hon J. The modified CAMDEX informant interview is a valid and reliable tool for use in the diagnosis of dementia in adults with Down's syndrome. Journal of Intellectual Disability Research 2004;48(6):611-620 (Pubitemid 39214380)
22. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue Issue 1. [DOI:%3Chtml%3E%3Cbody id=%22body%22%3EDOI: 10.1002/14651858.CD001190.pub2%3C/ body%3E%3C/html%3E]
23. Bishop J, Huether CA, Torfs C, Lorey F, Deddens J. Epidemiologic study of Down Syndrome in a racially diverse California population, 1989 - 1991. American Journal of Epidemiology 1997;145:134-147
24. Burt DB, Aylward EH. Test battery for the diagnosis of dementia in individuals with intellectual disability. Journal of Intellectual Disability Research 2000;44:175-180
25. Carpenter PK. Cardiovascular and autonomic function in Down syndrome - Prescribing implications. Br. J. Psychiatry 1995;167:118b-119b.
26. Casanova M,Walker L, Whitehouse P, Price D. Abnormalities of the nucleus basalis of Meynert in Down Syndrome. Annals of Neurology 1985;18:310-313 (Pubitemid 15023103)
27. Cooke L, Mohan M. Difficulties in Conducting Research in Vulnerable Groups (Rapid Response to Hewison 2006, BMJ, also cited in this review). BMJ 2006 (16 August);E-publication:Available http: //www.bmj.com/cgi/eletters/333/ 7562/300#139733.
28. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory. Neurology 1994;44:2308-2314.
29. Development Working Group, Sally-Ann Cooper. DC-LD: Diagnostic Criteria for Psychiatric Disorders for Use with Adults with Learn- ing Disabilities/mental Retardation. London: RCPsych Publications, 2001.
30. Deb S, Hare M, Prior L. Symptoms of dementia among adults with Down's syndrome: a qualitative study.. Journal of Intellectual Disability Research 2007;51:726-739 (Pubitemid 47249748)
31. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphic test. BMJ 1997;315(7):629-634. (Pubitemid 27387172)
32. Evenhuis H M. Further evaluation of the Dementia Questionnaire for Persons with Mental Retardation (DMR). Journal of Intellectual Disability Research 1996;40:369-373
33. Evenhuis HM, Kengen MMF, Eurlings HAL. Dementia Questionnaire for People with Intellectual Disabilities (DLD). Sydney: Pearson Psychocorp, 2006.
34. Fan WT. Psychiatry of learning disability - a time to sow, a time to grow. Hong Kong Journal of Psychiatry 2001;11(1):1-3.
35. Folstein MF, Foltein SE, McHugh PR. "Mini-mental state" A practical method for grading the cognitive state of patients for the clinicians. Journal of Psychiatric Research 1975;12:185-198
36. Fraser B. Psychopharmacology and people with learning disability. Advances in Psychiatric Treatment 1999;5:471-477
37. Gedye A. Dementia Scale for Down's Syndrome. Manual. Vancouver, BC: Gedye Research and Consulting, 1995.
38. Greenwood RD, Nadas AS. The clinical course of cardiac disease in Down's syndrome. Pediatric 1976;58:893.
39. Hemingway-Eltomey JM, Lerner AJ. Adverse effects of donepezil in treating Alzheimer's disease associated withDown's syndrome. American Journal of Psychiatry 1999;156(9):1470.
40. Hewison J, Haines A. Overcoming barriers to recruitment in health research. BMJ 2006;333:300-302
41. Higgins JPT, Thompson SG. Quantifying heterogeneity in a metaanalysis. Statistics in Medicine 2002;21:1539-1558.
42. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org Version 5.0.0 [updated February 2008].
43. Holland A J, Hon J, Huppert FA, et al. Population-based study of the prevalence and presentation of dementia in adults with Down's syndrome. British Journal of Psychiatry 1998;172:493-498 (Pubitemid 28247481)
44. Holland A J, Hon J, Huppert A, et al. Incidence and course of dementia in people with Down's syndrome: findings from a population-based study. Journal of Intellectual Disability Research 2000;44: 138-146 (Pubitemid 30386552)
45. Janicki MP. Developmental disabilities and Alzheimer's disease. Arlington, TX: The Arc of the United States, 1995.
46. Janicki MP, Dalton A. Prevalence of dementia and impact on intellectual disability services. Mental Retardation 2000;38:277-289
47. Margallo-Lana ML, Ballard C, Morris C Kay D, Tyrer S, Moore B. Cholinesterase inhibitors in the treatment of dementia. Int J Geriatr Psychiatry 2003;18:457-460
48. Mohan M, Bennett C, Carpenter PK. Galantamine for dementia in people with Down syndrome. Cochrane Database of Systematic Reviews 2009, Issue 1.[Art. No.: CD007656. DOI: 10.1002/14651858.CD007656]
49. Mohan M, Bennett C, Carpenter PK. Rivastigmine for dementia in people with Down syndrome. Cochrane Database of Systematic Reviews 2009, Issue 1.[Art. No.: CD007658. DOI: 10.1002/14651858.CD007658]
50. Mohan M, Bennett C, Carpenter PK. Memantine for dementia in people with Down syndrome. Cochrane Database of Systematic Reviews 2009, Issue 1.[Art. No.: CD007657. DOI: 10.1002/14651858.CD007657]
51. Moss MB, Albert MS, Butters N, et al. Differential patterns of memory loss among patients with Alzheimer's disease, Huntington's disease, and alcoholic Korsakoff 's syndrome. Archives of Neurology 1986; 43:239-246 (Pubitemid 16117835)
52. National Collaborating Centre for Mental Health. Dementia: A NICE-SCIE Guideline on Supporting People with Demen- tia and Their Carers in Health and Social Care (available online: http://www.scie.org.uk/publications/misc/ dementia/dementia-full- guideline.pdf, accessed November 2008). Leicester, UK: The British Psychological Society and Gaskell, 2006.
53. National Institute Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease: Guidance type: Technology appraisal. Accessible online: http: //www.nice.org.uk/guidance/index.jsp?action=download&o=36557 (last accessed May 2008). Vol. TA111, London: NICE, Date issued: September 2007.
54. Nihira K, Foster R, Shallhaas M, Leland H. AAMD Adaptive Behaviour Scale. Vol. 1974 Revision, Washington, DC: American Association on Mental Deficiency, 1974.
55. Prasher VP. Age-specific prevalence, thyroid dysfunction and depressive symptomatology in adults with Down syndrome and dementia. International Journal of Geriatric Psychiatry 1995;10:25-31.
56. Prasher VP, Percy M. Developmental disabilities in Ontario. Ohio: Front Porch Publishing, 1999.
57. Prasher V. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with downs syndrome: implications for the intellectual disability population. International Journal of Geriatrics Psychiatry 2004;19: 509-515 (Pubitemid 38877997)
58. Prasher V, Farooq A, Holder R. The Adaptive Behaviour Dementia Questionnaire (ABDQ): screening questionnaire for dementia in Alzheimer's disease in adults with Down syndrome. Research in Developmental Disabilities 2004;25(4):385-397 (Pubitemid 38749097)
59. Prasher VP. Personal communication. Email communications from Prof. V Prasher 24 and 25 April and telephone conversation 7 May 2008 clarifying specifics of the trial conditions April - May 2008.
60. Saxton J, MacGonigle KL, Swihart AA, Boller F. The severe impairment battery. Bury St Edmunds, Suffolk: Thames Valley Test Company, 1993.
61. Sekijima Y, Ikeda S, Tokuda T, Satoh S, Hidaka H, Hidaka E, et al. Prevalence of dementia of Alzheimer type and apolipoprotein E phenotypes in aged patients with Down's syndrome. European Neurology 1998;39:331-335 (Pubitemid 28230404)
62. Shigeta M, Homma A. Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles. CNS Drug Review 2001;7(4):353-368 (Pubitemid 34263871)
63. Stanton LR, Coetzee RH. Downs syndrome and dementia. Advances in Psychiatric Treatment 2004;10:50-58
64. Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, et al. Presence of soluble amyloid B - Peptide precedes amyloid plaque formation in Down's syndrome. Nature Medicine 1996;2:93-95 (Pubitemid 126664328)
65. Visser FE, Aldenkamp AP, van Huffelen AC, Kuilman M, Overweg J, van Wijk. Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down Syndrome. American Journal of Mental Retardation 1997;101:400-412 (Pubitemid 27061358)
66. Wisniewski KE, Wisniewski HM, Wen GY. Occurence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Annals of Neurology 1995;17:278-282
67. Yoo JH, Valdovinos MG, Williams DC. Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature. Journal of Autism & Developmental Disorders 2007;37 (10):1883-1901
68. Zigman W, Silverman W, Wisniewsi H. Aging and Alzheimer's disease in Down Syndrome: Clinical and pathological changes in Down Syndrome: Clinical and pathological changes. Mental Retardation & Developmental Disability Research Reviews 1996;2(2):73-79